Dental applications for a novel osteoclast inhibitor
Dental applications for a novel osteoclast inhibitor
批准号:
8118169
负责人:
LEXIE Shannon HOLLIDAY
金额:
$18.13万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-08-01 至 2013-07-31
关键词:
ActinsAdverse effectsAlkaline PhosphataseAlveolar Bone LossAnimal ModelAntibiotic ResistanceAntibioticsBindingBiological AssayBiological ModelsBone ResorptionBone necrosisCalcitriolCellsClinicalComputersCytoskeletonDataDentalDental CareDentistryDevelopmentDiseaseElementsElvaxEndodonticsEvaluationFamilyFerretsFluoroquinolonesFunctional disorderFundingFutureGoalsGrantIn VitroInhibitory Concentration 50LeftLinkMalignant Bone NeoplasmMarrowMediatingMembraneMethodsMicroRNAsMicrofilamentsModelingMusMuscleNamesNew AgentsOralOrthodonticOryctolagus cuniculusOsteoblastsOsteoclastsOsteoporosisPeptidesPeriodontal DiseasesPeriodontal InfectionPeriodontic specialtyPeriodontitisPhysiologyPreclinical TestingProceduresPublishingRattusReportingResearchResearch DesignResearch SupportRodent ModelRoot ResorptionSurfaceSystemTestingTherapeuticTherapeutic AgentsTimeTissuesTooth LossTooth MovementTooth structureTubeUnited States National Institutes of Healthbasebisphosphonatebonecell growthdecaneefficacy testingexperienceimplantationin vitro Assayin vitro Modelinhibitor/antagonistinnovationmembermineralizationnoveloral tissueosteoclastogenesispreclinical studypublic health relevanceresearch clinical testingresearch studysmall moleculesupercomputertraffickingvacuolar H+-ATPase
中文摘要
描述(由申请人提供):依诺沙星和BEL 16最近在体外试验中被鉴定为破骨细胞形成和功能的新型抑制剂。以前的研究表明,液泡H+ ATP酶(V-ATP酶)的B亚基和肌动蛋白丝之间的相互作用的抑制剂应该阻止破骨细胞吸收骨的能力。基于计算机的小分子筛选预测结合亚基B的肌动蛋白结合表面并抑制其与肌动蛋白丝的相互作用,鉴定为依诺沙星和Bcl 16。这些分子随后显示出在试管中阻断纯兔肌肉肌动蛋白丝与B亚基的结合。在骨化三醇刺激的小鼠骨髓培养物中,测试依诺沙星和BAB 16对体外破骨细胞形成和功能的影响。两者在约10 μ M的浓度下阻断破骨细胞形成和预分化破骨细胞的功能。与此相反,这些分子没有检测到的影响骨髓培养中产生的成骨细胞的数量,判断碱性磷酸酶阳性细胞的数量,或对MC 3 T3-E1成骨细胞。这些数据表明,依诺沙星和BEL 16可能通过新的机制抑制破骨细胞,而对成骨细胞没有抑制作用。本提案的总体目标是进行初步试验,以确定依诺沙星和BEL 16是否有望作为治疗各种牙科应用的药物,其中抑制骨吸收将是有益的。提出了以下中心假设:依诺沙星和BERN 16是通过靶向与肌动蛋白细胞骨架结合的V-ATP酶来抑制骨吸收的一类新治疗剂的第一个例子。提出了四个具体目标。在目的1中,我们将开发一种利用Elvax局部缓释依诺沙星和B16的方法。许多研究已经将Elvax用于类似的应用。在目标2中,将在良好建立的牙周炎大鼠模型中测试依诺沙星和BEL 16减少牙周骨损失的能力。目的3将测试用依诺沙星和B16治疗是否减少与利用已建立的雪貂系统的再植入相关的再吸收。目的4在大鼠模型中测试依诺沙星和B16阻断正畸牙齿移动的能力。这可以提供一种新的手段,提供正畸锚固。这项研究应提供初步的证据,关于潜在的V-ATP酶-肌动蛋白相互作用的抑制剂用于牙科手术。为了提供足够的初步数据以确定大规模临床前研究是否合理,需要对当前研究提供支持。鉴于拟议的研究代表了将生物活性小分子用于牙科应用的一种新的创新方法,并可能产生巨大的临床影响,我们认为NIH以R21赠款的形式提供支持是必要的。
公共卫生相关性:抑制骨吸收的生物活性剂可用于各种牙科应用。新的破骨细胞功能的小分子抑制剂,依诺沙星和BERNIA 16,已被确定使用基于超级计算机的测定。目前的提案将在动物模型中进行这些分子的临床前试验,以检查它们是否适合牙周病,牙髓病和正畸用途。
英文摘要
DESCRIPTION (provided by applicant): Enoxacin and Binhib16 were recently identified as novel inhibitors of osteoclast formation and function in in vitro assays. Previous studies had indicated that inhibitors of an interaction between the B-subunit of vacuolar H+ATPase (V-ATPase) and actin filaments should block the ability of osteoclasts to resorb bone. A computer based screen for small molecules predicted to bind the actin binding surface of subunit B and inhibit its interaction with actin filaments identified enoxacin and Binhib16. These molecules were then shown to block binding of pure rabbit muscle actin filaments to B-subunit in the test tube. Enoxacin and Binhib16 were tested for effects on osteoclast formation and function in vitro in calcitriol-stimulated mouse marrow cultures. Both blocked osteoclast formation and the function of pre-differentiated osteoclasts at a concentration of approximately 10 <M. In contrast, these molecules did not have detectable effects on the number of osteoblasts produced in marrow cultures, as judged by the number of alkaline phosphatase positive cells, or on MC3T3-E1 osteoblasts. These data suggest that enoxacin and Binhib16 might inhibit osteoclasts by novel mechanisms, without having inhibitory effects on osteoblasts. The overall goal of this proposal is to perform preliminary tests to determine whether enoxacin and Binhib16 hold promise as agents for use in the treatment of various dental applications in which inhibition of osteoclastic bone resorption would be beneficial. The following central hypothesis is proposed: Enoxacin and Binhib16 are the first examples of a new class of therapeutic agents for the inhibition of osteoclastic bone resorption by targeting V-ATPase binding to the actin cytoskeleton. Four specific aims are suggested. In Aim 1, we will develop a method for sustained local release of enoxacin and Binhib16 making use of Elvax. Numerous studies have utilized Elvax for similar applications. In Aim 2, enoxacin and Binhib16 will be tested for its capacity to reduce periodontal bone loss in a well-established rat model of periodontitis. Aim 3 will test whether treatment with enoxacin and Binhib16 reduces resorption associated with re- implantation making use of an established ferret system. Aim 4 will test the capacity of enoxacin and Binhib16 to block orthodontic tooth movement in a rat model. This could provide a novel means for providing orthodontic anchorage. This study should provide initial evidence regarding the potential of inhibitors of V-ATPase-actin interactions for use in dental procedures. Support for the current studies is necessary in order to provide sufficient preliminary data to determine whether large scale pre-clinical studies are justified. Given that the proposed research represents a fresh and innovative approach to the use of bioactive small molecules for dental applications, and could have a large clinical impact, we believe that NIH support in the form of an R21 grant is warranted.
PUBLIC HEALTH RELEVANCE: A bioactive agent that inhibits osteoclastic bone resorption would be useful for various dental applications. Novel small molecule inhibitors of osteoclast function, enoxacin and Binhib16, have been identified using a supercomputer-based assay. The current proposal will conduct pilot preclinical tests of these molecules in animal models to examine their suitability for periodontic, endodontic and orthodontic uses.
期刊论文(6)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1038/s41598-018-34698-9
发表时间:
2018-11-01
期刊:
Scientific reports
影响因子:
4.6
作者:
[Vracar TC, Zuo J, Park J, Azer D, Mikhael C, Holliday SA, Holsey D, Han G, VonMoss L, Neubert JK, Rody WJ Jr, Chan EKL, Holliday LS]
通讯作者:
Holliday LS
Editorial: vacuolar H(+)-ATPase: targeting a "housekeeping" enzyme for drug development.
社论:液泡 H(+)-ATP 酶:针对药物开发的“管家”酶。
DOI:
10.2174/138920312800493214
发表时间:
2012
期刊:
Current protein & peptide science
影响因子:
2.8
作者:
[Holliday,LShannon]
通讯作者:
Holliday,LShannon
DOI:
10.1902/jop.2014.140302
发表时间:
2015-01
期刊:
Journal of periodontology
影响因子:
4.3
作者:
[Oktay S, Chukkapalli SS, Rivera-Kweh MF, Velsko IM, Holliday LS, Kesavalu L]
通讯作者:
Kesavalu L
DOI:
10.1371/journal.pone.0092119
发表时间:
2014
期刊:
PloS one
影响因子:
3.7
作者:
[Rivera MF, Chukkapalli SS, Velsko IM, Lee JY, Bhattacharyya I, Dolce C, Toro EJ, Holliday LS, Kesavalu L]
通讯作者:
Kesavalu L
DOI:
10.1111/j.1601-6343.2009.01443.x
发表时间:
2009-05
期刊:
Orthodontics & craniofacial research
影响因子:
3.1
作者:
[L. Holliday;D. Ostrov;T. Wronski;C. Dolce]
通讯作者:
L. Holliday;D. Ostrov;T. Wronski;C. Dolce
Exosomes in Alveolor Bone Remodeling and Root Resorption
-
批准号:8771645
-
项目类别:
-
资助金额:$22.5万
-
财政年份:2014
-
负责人:LEXIE Shannon HOLLIDAY
-
依托单位:
Dental applications for a novel osteoclast inhibitor
-
批准号:7894165
-
项目类别:
-
资助金额:$21.98万
-
财政年份:2010
-
负责人:LEXIE Shannon HOLLIDAY
-
依托单位:
Osteoclast activation in uremic bone disease
-
批准号:6368891
-
项目类别:
-
资助金额:$23.6万
-
财政年份:2001
-
负责人:LEXIE Shannon HOLLIDAY
-
依托单位:
Osteoclast activation in uremic bone disease
-
批准号:6512129
-
项目类别:
-
资助金额:$24.02万
-
财政年份:2001
-
负责人:LEXIE Shannon HOLLIDAY
-
依托单位:
Osteoclast activation in uremic bone disease
-
批准号:6612941
-
项目类别:
-
资助金额:$24.02万
-
财政年份:2001
-
负责人:LEXIE Shannon HOLLIDAY
-
依托单位:
Osteoclast activation in uremic bone disease
-
批准号:6915600
-
项目类别:
-
资助金额:$24.02万
-
财政年份:2001
-
负责人:LEXIE Shannon HOLLIDAY
-
依托单位:
Osteoclast activation in uremic bone disease
-
批准号:6772566
-
项目类别:
-
资助金额:$24.02万
-
财政年份:2001
-
负责人:LEXIE Shannon HOLLIDAY
-
依托单位:
海外基金